## Atrial fibrillation and stroke





Isabelle C Van Gelder
University Medical Center Groningen
The Netherlands



- Stroke what is the problem for patients with AF?
- Does abolishing AF prevents stroke ?
- Is AF a mechanism or just a marker for stroke ?
- AF is progressive disease and AF progression is associated with stroke, heart failure and mortality






Stroke – what is the problem for patients with AF?





#### AF and HRs for stroke and other vascular events


Primary care research database, UK population (87% white) Linked with secondary care data and cause-specific mortality data 4.3 million adults, included at standard GP with 1 RR 1990-2013 FU 7 yrs





Iniversity Medical Center Groningen

### Individuals with stroke








- Stroke what is the problem for patients with AF?
- Does abolishing AF prevents stroke ?







## Early treatment of AF for Stroke prevention Trial EAST

#### Pre-Study Screening

# Patients at risk for cardiovascular events

 $(\approx CHA_2DS_2VASc score \geq 2^*)$ 

#### and having

recent onset atrial fibrillation (≤ 1 year duration or first documented by ECG)

#### \*Detailed inclusion criteria:

One of the following: age > 75 years or prior stroke / TIA

OR

Two of the following: age > 65 years; female sex; arterial hypertension; diabetes mellitus; previous myocardial infarction, CABG or PCI; stable heart failure (NYHA II or LVEF<50%); left ventricular hypertrophy (>15 mm wall thickness); chronic kidney disease (MDRD stage III - IV); peripheral artery disease.

#### **Study Procedures**

#### **Early Rhythm Control**

anticoagulation, rate control and either antiarrhythmic drug therapy or pulmonary vein isolation (PVI)

in case of recurrent AF:
Re-PVI, adaptation of antiarrhythmic
drug therapy

ECG monitoring of therapy

#### **Usual Care**

anticoagulation, rate control, supplemented by rhythm control only in symptomatic patients on optimal rate control therapy

outpatient FU at 12, 24, 36 moths (both study groups) therapy of underlying heart disease (both study groups) blind assessment of primary outcomes (both study groups)






Randomisation

- Stroke what is the problem for patients with AF?
- Does abolishing AF prevents stroke ?
- Is AF a mechanism or just a marker for stroke ?






## Temporal disconnect











Parekh et al. Circ 2006

University Medical Center Groningen

## AF: mechanism or marker for stroke?

SCAF episodes are associated with AF but only a minority had SCAF in the month before their stroke






# AF and stroke – mechanism more complicated



## AF: mechanism or marker for stroke?







- Stroke what is the problem for patients with AF?
- Does abolishing AF prevents stroke ?
- Is AF a mechanism or just a marker for stroke ?
- AF is progressive disease and AF progression is associated with stroke, heart failure and mortality





# AF progression is associated with vascular risks

	n	FU, years	AF progression
Euro Heart Survey AF, 2010	1219	1	15%
Record-AF, 2012	2137	1	15%

De Vos, Crijns, Euro Heart Survey JACC 2010	AF progression	No AF progression	p value
CV admissions (%)	71 %	50 %	<0.001
Stroke	6 %	2 %	0.003
CV mortality	7 %	3 %	0.005






## Risk of ischemic stroke or embolism in SCAF

c	Clinical Outcome	Subclinical Atrial Tachyarrhythmias between Enrollment and 3 Months				Hazard Ratio with Subclinical Atrial Tachyarrhythmias (95% CI)	P Value
		Pres (N=	<b>1</b>	Absent (N = 2319)			
		no. of events	%/yr	no. of events	%/yr		
ŀ	schemic stroke or systemic embolism*	11	1.69	40	0.69	2.49 1.28–4.85)	0.007
	Ischemic stroke	10	1.54	36	0.62	2.52 (1.25–5.08)	0.01
L	Systemic embolism	1	0.15	4	0.07	2.24 (0.25–20.10)	0.47





# Longer subclinical AF: higher risk of stroke








### Conclusions


- Stroke is still a significant problem in AF, next to heart failure
- Mechanism of stroke in AF still not completely known
- AF mechanism or bystander of stroke, anyway AF often increases risk of stroke





# CHA<sub>2</sub>DS<sub>2</sub>-VASc score is not static!





CHA<sub>2</sub>DS<sub>2</sub>-VASc score:

- Not static
- Most pts with ischemic stroke developed ≥1 new stroke risk factor






- Stroke what is the problem for patients with AF?
- Does abolishing AF prevents stroke ?
- Is AF a mechanism or just a marker for stroke ?
- AF is progressive disease and AF progression is associated with stroke, heart failure and mortality
- Hypercoagulability not only mechanism of stroke but also of AF progression ?





# Hypercoagulability and remodeling







# Hypercoagulability and remodeling

 Hypercoagulability represents a so far unrecognized key mechanism in atrial remodeling and AF progression







# Hypercoagulability associated with atrial remodeling

**Fibroblasts** Xa Hyperincubated with coagulability thrombin **Thrombin** Cardiac fibroblast IL-6 TGF-β MCP-1 Pro-fibrotic and Dedifferentiation Collagen synthesis inflammatory (Myofibroblasts) cytokines <sup>3</sup>H-proline incorporation α-SMA MCP-1 +120% Thrombin (0.01U/ml) +72% +200% ns Thrombin + Dabigatran ns ns funded by the





## Thrombin promotes AF





## Hypercoagulability and remodeling











# Hypothesis RACE V

- Hypercoagulability is one of the key mechanisms in AF progression (permanent AF and CV morbidity and mortality)
- Hypercoagulability varies depending on duration of AF and severity of the underlying vascular diseases
- Thrombin inhibitors, Factor Xa inhibitors and vitamin K antagonists differ with respect to prevention of AF progression







# Study design RACE V

- Multicenter, prospective, observational study
- 750 patients with self-terminating AF
  - Extensive phenotyping and characterization
  - Continuous rhythm monitoring
- Total inclusion duration 2 years
- Total follow-up 2.5 years
- Main study endpoint AF progression
- Expected AF progression rate 10%/ year → 187 AF progression events






# Continuous rhythm monitoring RACE V

Medtronic Advisa Pacemaker

Medtronic Reveal LINQ
















- 65 year old female
- Symptomatic atrial fibrillation
- Risk factor for AF hypertension
- Near collaps ~19.15 h









- Stroke what is the problem for patients with AF?
- Does abolishing AF prevents stroke ?
- Is AF a mechanism or just a marker for stroke ?
- AF is progressive disease and AF progression is associated with stroke, heart failure and mortality
- Hypercoagulability not only mechanism of stroke but also of AF progression ?





#### ILR diagnostics

#### Diagnoses / treatments



Red ILR alert

- Asystole/ pause > 4.5 sec
- Sustained bradycardia < 30/min
- Sustained tachycardia > 182/min
- Sustained VT>182 bpm
- Any torsade des pointes (TdP)

Admission agnostic work-up COMPASS RV and Activity - Pacemaker ajustments as needed

- Adjust AAD: control AF(L)
- Adjust AAD, electrolytes: prevent TdP
- Adjust rate control / heart failure drugs
- Consider acute catheter ablation / ECV
- ACS therapy / PCI as needed

Yellow ILR alert

Patient reports

with

**Symptoms** 

Successive AF(L) or AT >20 beats

- AF progression
- Sinus arrests, sympt. bradycardia
- Progressive sinus tachycardia \*

Admission Diagnostic work-u

COMPASS

- Cardioversion if persistent AF

- Consider catheter ablation
- Pacemaker as needed
- Adjust AAD: control AF(L)/ prevent TdP
- Adjust rate control / heart failure drugs
- Antithrombotics / PLAAO as needed
- ACS therapy / PCI as needed
- Blood pressure management

#### Red alert

- should be dealt with within one working day, subject to care by in-house 24/7 care service

Yellow alert or symptomatic patient

- Should be dealt with within 1 week

#### **COMPASS** guided diagnosis

- Decreased HRV and/or activity support heart failure, uncontrolled hypertension, or points to impact of AF w/o tachycardia if any episodes
- Increased HRV supports SSS

\*) COMPASS current heart rate being > 1 week more than 25% or > 20 bpm higher than initial or set point heart rate; may indicate heart failure














# 1 month – 53 patients Event Types


#### **Transmissions Classification**



338 Transmissions reviewed

181 Transmissions with events (in charts)


Transmissions with red or amber events in 17 patients











## FOCUS**ON**™

#### SUBJECT TACHY

All,

Episode ID#	Episode Date and Time	Report type	Comment
7 - 16	maart 2017	Full 8 maart 2017 15:43	CareAlert AF, alle episoden tonen AF/PAF met snelle kamerrespons. Tevens zijn er een aantal breed comple tachycardieen zichtbaar max duur 2 seconden (#9) mogelijk VT, SVT/AT aberrante geleiding niet uitgesloten.










35 year old male





### Conclusions

- Remote monitoring of patients with implantable cardiac devices has benefits both for patients and physicians
  - Earlier detection of clinically relevant events not limited to SCAF
  - Probable a reduction of health care costs and consumption
- However, an issue is how to handle all those data efficiently
- The FOCUS**ON**<sup>TM</sup> monitoring and triaging center may help to manage an adequate handling of all transmitted ECG data
- And it may potentially help to improve cardiovascular outcome





## Thank you for your attention











## AF is progressive disease

- AF is the most frequent arrhythmia: > 1 million will have AF by 2040
- AF is not benign being associated with MACCE
- AF is a growing health care problem

## Atrial Fibrillation is a progressive disease

... often progresses from <u>self-terminating</u> to <u>non-selfterminating</u> AF

	n	FU, years	AF progression
Euro Heart Survey AF, 2010	1219	1	15%
Record-AF, 2012	2137	1	15%



